[go: up one dir, main page]

DE69739372D1 - Verfahren und zusammensetzungen zur genetisch schützenden und therapeutischen immunisierung - Google Patents

Verfahren und zusammensetzungen zur genetisch schützenden und therapeutischen immunisierung

Info

Publication number
DE69739372D1
DE69739372D1 DE69739372T DE69739372T DE69739372D1 DE 69739372 D1 DE69739372 D1 DE 69739372D1 DE 69739372 T DE69739372 T DE 69739372T DE 69739372 T DE69739372 T DE 69739372T DE 69739372 D1 DE69739372 D1 DE 69739372D1
Authority
DE
Germany
Prior art keywords
genetically
compositions
protective
therapeutic immunization
immunization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69739372T
Other languages
English (en)
Inventor
Immunity Kft. Genetic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE69739372D1 publication Critical patent/DE69739372D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • C12N2740/16062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69739372T 1996-02-21 1997-02-20 Verfahren und zusammensetzungen zur genetisch schützenden und therapeutischen immunisierung Expired - Lifetime DE69739372D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60462796A 1996-02-21 1996-02-21
PCT/US1997/002933 WO1997031119A1 (en) 1996-02-21 1997-02-20 Methods and compositions for protective and therapeutic genetic immunization

Publications (1)

Publication Number Publication Date
DE69739372D1 true DE69739372D1 (de) 2009-06-04

Family

ID=24420371

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69739372T Expired - Lifetime DE69739372D1 (de) 1996-02-21 1997-02-20 Verfahren und zusammensetzungen zur genetisch schützenden und therapeutischen immunisierung

Country Status (12)

Country Link
EP (1) EP0882134B8 (de)
JP (1) JP2000517290A (de)
AP (1) AP964A (de)
AT (1) ATE429505T1 (de)
AU (1) AU726623B2 (de)
CA (1) CA2246359A1 (de)
DE (1) DE69739372D1 (de)
EA (2) EA003554B1 (de)
ES (1) ES2324745T3 (de)
NZ (1) NZ331369A (de)
OA (1) OA10842A (de)
WO (1) WO1997031119A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3210997A (en) * 1996-05-24 1997-12-09 University Of Maryland At Baltimore Dna vaccines for eliciting a mucosal immune response
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
WO1999013915A1 (en) * 1997-09-15 1999-03-25 Genetic Immunity, Llc. Method of delivering genes to antigen presenting cells of the skin
CA2314683A1 (en) * 1997-12-12 1999-06-24 Luigi Naldini Therapeutic use of lentiviral vectors
WO1999047146A1 (en) * 1998-03-17 1999-09-23 Julianna Lisziwiewicz Anti-hiv combination comprising hydroxyurea, ddi, and a protease inhibitor
US6461616B1 (en) * 2000-09-09 2002-10-08 Akzo Nobel Nv EIAV p26 deletion vaccine and diagnostic
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
CA2950109C (en) 2000-10-27 2019-02-19 John W. Hadden Vaccine immunotherapy for immune suppressed patients
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US7097842B2 (en) 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
HU230198B1 (hu) 2000-11-23 2015-10-28 Bavarian Nordic A/S Módosított Vacciniavírus Ankara-variáns
DK1372708T3 (da) 2001-02-13 2008-10-20 Us Gov Sec Army Vaccine til transkutan immunisering mod rejsediarre
EP2345665A3 (de) 2001-12-04 2012-02-15 Bavarian Nordic A/S Impfstoff aus der NS1-Untereinheit eines Flavivirus
ES2288609T5 (es) 2002-04-19 2017-11-13 Bavarian Nordic A/S Virus vaccinia ankara modificado para la vacunación de neonatos
DE60320520T3 (de) 2002-09-05 2019-05-09 Bavarian Nordic A/S Verfahren zur amplifikation von einem poxvirus in serumfreien verhältnissen
WO2004065575A2 (en) * 2003-01-15 2004-08-05 Research Institute For Genetic And Human Therapy (Right) Dna compositon and uses thereof
FR2872170B1 (fr) * 2004-06-25 2006-11-10 Centre Nat Rech Scient Cnrse Lentivirus non interactif et non replicatif, preparation et utilisations
WO2006135413A2 (en) * 2004-09-02 2006-12-21 Qun Chen Encapsidation system for production of recombinant virus-like particles
GB0526211D0 (en) * 2005-12-22 2006-02-01 Oxford Biomedica Ltd Viral vectors
EP2150618B1 (de) 2007-05-04 2017-10-11 University Health Network Il-12-immuntherapie gegen krebs
US7993660B2 (en) 2007-11-28 2011-08-09 Irx Therapeutics, Inc. Method of increasing immunological effect
WO2010009465A2 (en) * 2008-07-18 2010-01-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Htlv-ii vector and methods of use
EP2429585B1 (de) 2009-05-15 2018-04-18 IRX Therapeutics, Inc. Impfstoff-immuntherapie
CN103097543A (zh) 2009-12-08 2013-05-08 伊尔克斯治疗有限公司 逆转朗格汉斯细胞免疫抑制的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5738852A (en) * 1993-04-20 1998-04-14 Solis Therapeutics, Inc. Methods of enhancing antigen-specific T cell responses
US6080408A (en) * 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles

Also Published As

Publication number Publication date
JP2000517290A (ja) 2000-12-26
EA003554B1 (ru) 2003-06-26
ATE429505T1 (de) 2009-05-15
AU2136997A (en) 1997-09-10
EP0882134B8 (de) 2009-09-02
EA002020B1 (ru) 2001-12-24
EA200100302A1 (ru) 2001-10-22
AP9801320A0 (en) 1998-09-30
OA10842A (en) 2001-08-14
WO1997031119A1 (en) 1997-08-28
EA199800746A1 (ru) 1999-02-25
NZ331369A (en) 2001-04-27
AP964A (en) 2001-05-11
EP0882134A1 (de) 1998-12-09
CA2246359A1 (en) 1997-08-28
AU726623B2 (en) 2000-11-16
EP0882134B1 (de) 2009-04-22
ES2324745T3 (es) 2009-08-13

Similar Documents

Publication Publication Date Title
DE69739372D1 (de) Verfahren und zusammensetzungen zur genetisch schützenden und therapeutischen immunisierung
DE69519235D1 (de) Hämorrhoidenzusammensetzungen und verfahren zur verwendung
DE69938870D1 (de) Verfahren zur verbesserten bilderzeugung und photodynamischen therapie
ATE351910T1 (de) Ob-fusionsprotein enthaltende zusammensetzungen und verfahren
DE69534416D1 (de) Verfahren und formulierungen zur bekämpfung von schadinsekten
DE69816789D1 (de) Verfahren und system zur gestengesteuerten optionsauswahl
DE69707325D1 (de) Bilderzeugungsmaterial und Verfahren
DE69834401D1 (de) Businterfacesystem und verfahren
DE69721322D1 (de) Zusammensetzung und verfahren zur keimungshemmung bei kartoffeln
DE69635445D1 (de) Alkalialuminiumhydroxycarbonatzusammensetzung und verfahren zur herstellung
DE69834242D1 (de) Strahlungsthermometer und verfahren zu seiner justierung
DE69517683D1 (de) Alpha-galactosyl-epitope enthaltende zusammensetzungen und verfahren für impfstoffe
DE69822873D1 (de) Zusammensetzungen und verfahren zur gewichtsverringerung
DE69511080D1 (de) Schnittstellenanordnung und verfahren
ATE283116T1 (de) Passivierungszusammensetzung und verfahren zum beschichten
DE69602847D1 (de) Tuberkilizide synergistische desinfizierende zusammensetzung und verfahren zur desinfektion
DE69832282D1 (de) Polysilazan-amine und verfahren zur herstellung
DE69711825D1 (de) Läppvorrichtung und Verfahren
DE69714323D1 (de) Gerät und Verfahren zur Bilderzeugung
DE19782204T1 (de) Verlängerungseinrichtung und Verfahren
DE69718502D1 (de) Zahnärztliche zusammensetzung, system und verfahren
DE69514936D1 (de) Kühlsystem und verfahren
DE69710213D1 (de) Interaktives gerät und verfahren
DE69402522D1 (de) Brandschutzhülle und verfahren zur erzeugung derselben
EP1075184A4 (de) Zusammensetzungen und verfahren zur aktiven impfung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition